We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid COVID-19 Antigen Tests Less Effective at Detecting SARS-CoV-2 in People with Low Virus Levels, Finds Study

By LabMedica International staff writers
Posted on 22 Oct 2020
Researchers from the Erasmus University Medical Center (Rotterdam, the Netherlands) have cautioned that not all rapid COVID-19 antigen tests that provide results within 30 minutes may be equally effective at detecting the SARS-CoV-2 virus.

Their suggestion was based on data gathered from drive through testing stations using rapid antigen detection tests (RDTs), RT-PCR and virus culture, with the aim of assessing the ability of RDTs to detect infectious cases. More...
Antigen-based assays detect specific surface proteins, or antigens, on SARS-CoV-2 particles, and are easy to use and inexpensive to produce. The researchers used five commercially available rapid antigen assays on samples from 1,754 people who had already tested positive for the SARS-CoV-2 virus with the standard PCR test, which is highly sensitive but slow.

The team found that the detection limits of the five commercially available RDTs differed considerably, impacting the translation into the detection of infectious cases. The two most sensitive tests detected the SARS-CoV-2 virus more than 97% of the time, whereas the least sensitive test detected the novel coronavirus in about 75% of the cases. All the samples came from people with COVID-19 symptoms, who tend to have high levels of the SARS-CoV-2 virus. Based on their findings, the researchers have cautioned that rapid antigen tests may be less effective at picking up the presence of the SARS-CoV-2 virus in people with low levels of the virus. The researchers have recommended careful fit-for-purpose testing before implementation of antigen RDTs in routine testing algorithms as part of the COVID-19 response.

Related Links:
Erasmus University Medical Center


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.